Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.
- WALTHAM, Mass., Oct. 24, 2023 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer.
- Dr. Fink will be responsible for all aspects of Q32 Bio's chemistry, manufacturing and control (CMC)-related activities.
- "We are thrilled to welcome Saul to the Q32 Bio team to take the helm of our manufacturing operations," said Jodie Morrison, who has assumed the role of Q32's long-term Chief Executive Officer from her previous position as acting CEO.
- "I am delighted to join Q32 Bio at this exciting stage of the Company's growth," said Dr. Fink.